NAUT (Nautilus Biotechnology) EBITDA Margin %: 0.00% (As of Mar. 2026)


NAUT Nautilus Biotechnology Inc NAUT
28 GF Score
Price $2.38
! 2 Warning Signs
View Full Analysis

What is Nautilus Biotechnology EBITDA Margin %?

Nautilus Biotechnology NAUT +2.15% 28 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates NAUT with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, Nautilus Biotechnology ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nautilus Biotechnology's EBITDA for the three months ended in Mar. 2026 was $-14.65 Mil. Nautilus Biotechnology's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Nautilus Biotechnology's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Nautilus Biotechnology  (NAS:NAUT) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Nautilus Biotechnology EBITDA Margin % Related Terms

Nautilus Biotechnology EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Nautilus Biotechnology's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nautilus Biotechnology EBITDA Margin % Chart

Nautilus Biotechnology Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Nautilus Biotechnology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NAUT vs IFRX, NMRA, IRD: EBITDA Margin % Comparison

For the Biotechnology subindustry, Nautilus Biotechnology's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nautilus Biotechnology EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nautilus Biotechnology's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Nautilus Biotechnology's EBITDA Margin % falls into.


NAUT
28GF Score
Nautilus Biotechnology Inc NAUT
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nautilus Biotechnology EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Nautilus Biotechnology's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-60.372/0
= %

Nautilus Biotechnology's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-14.648/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Nautilus Biotechnology (NAUT) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nautilus Biotechnology and its competitors. According to the industry distribution chart, Nautilus Biotechnology ranks #999999 out of 945 companies in the Biotechnology industry.
Is Nautilus Biotechnology's EBITDA Margin % too high?
Nautilus Biotechnology's current EBITDA Margin % is 0.00%. Based on the distribution chart, Nautilus Biotechnology ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nautilus Biotechnology has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Nautilus Biotechnology's EBITDA Margin % compare to IFRX and NMRA?
According to the Biotechnology industry distribution chart, Nautilus Biotechnology ranks #999999 out of 945 companies for EBITDA Margin %. This places Nautilus Biotechnology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nautilus Biotechnology and its competitors. Nautilus Biotechnology's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nautilus Biotechnology stock overvalued right now?
Nautilus Biotechnology (NAUT) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Nautilus Biotechnology's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nautilus Biotechnology (NAUT), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nautilus Biotechnology Business Description

Address 2701 Eastlake Avenue East, Seattle, WA, USA, 98102
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
28GF Score

Get the complete analysis for NAUT

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.38
Price